Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer

References

• Anonymous. 1996. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer by the American Society of Clinical Oncology. Journal of Clinical Oncology 14:2843–2877.
   PubMed Web of Science ®Google Scholar
• Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. European Journal of Cancer 1994; 30: 2082–2084
   Google Scholar
• Bon GS, von Mensdorff-Poully S, Kenemans P, van Kamp GJ, Verstraeten RA, Hilgers J. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assay. Clinical Chemistry 1997; 43: 585–93
   PubMedGoogle Scholar
• Buamah P. Benign conditions associated with raised serum CA 125 concentration. Journal of Surgical Oncology 2000; 75: 264–265
   PubMed Web of Science ®Google Scholar
• Canizares F, Sola J, Perez M, Tovar I, De Las Heras M, Salinas J, et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumor Biology 2001; 22: 273–81
   PubMedGoogle Scholar
• Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clinical Chemistry 2003; 49: 1579–1598
   PubMedGoogle Scholar
• Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER-2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Research 1999; 59: 1196–1201
   PubMed Web of Science ®Google Scholar
• Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, et al. Circulating HER-2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clinical Cancer Research 2000; 6: 2356–2362
   PubMed Web of Science ®Google Scholar
• Doroudchi M, Talei A, Modjtahedi H, Dehaghani AS, Pezeshki AM, Thomas H, et al. Serum level of HER-2 extracellular domain in Iranian patients with breast cancer: a follow-up study. Iranian Journal of Immunology 2005; 2: 191–199
   Google Scholar
• Duffy MJ, Shering SG, Sherry F, McDermott E, O'Higgins N. 1996. CA 15-3, a circulating marker with strong prognostic value in breast cancer, new observation. In: Martin SM, Halloran SPProceedings of the XVI International Congress of Clinical Chemists. London: Association of Clinical Biochemists. Abstract A407.
   Google Scholar
• Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Annals of Clinical Biochemistry 1999; 36: 579–586
   PubMedGoogle Scholar
• Eskelinen M, Kataja V, Hamalainen E, Kosma VM, Penttila I, Alhava E. Serum tumor markers CEA, AFP, CA15-3, TPS and neu in diagnosis of breast cancer. Anticancer Research 1997; 17: 231–234
   PubMedGoogle Scholar
• Gendler SJ, Spicer AP. Epithelial mucin genes. Annual Review of Physiology 1995; 57: 607–634
   PubMed Web of Science ®Google Scholar
• Geraghty J, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ. CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 1992; 70: 2831–2834
   PubMedGoogle Scholar
• Hardardottir H, Parmley TH 2nd, Quirk JG, Jr, Sanders MM, Miller FC, O'Brien TJ. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. American Journal of Obstetrics & Gynecology 1990; 163: 1925–1931
   PubMed Web of Science ®Google Scholar
• Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. Journal of Clinical Oncology 2001; 19: 1698–1706
   PubMed Web of Science ®Google Scholar
• Hayes DF, Zurawski VR, Kufe D. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. Journal of Clinical Oncology 1986; 4: 1542–1550
   PubMed Web of Science ®Google Scholar
• Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring and treatment of primary and metastatic breast carcinoma. Oncologist 2006; 11: 541–552
   PubMed Web of Science ®Google Scholar
• Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clinical Cancer Research 2003; 9: 4423–4434
   PubMed Web of Science ®Google Scholar
• Kong S-Y, Kang JH, Kwon Y, Kang H-S, Chung K-W, Kang SH, et al. Serum HER-2 concentration in patients with primary breast cancer. Journal of Clinical Pathology 2006; 59: 373–376
   PubMed Web of Science ®Google Scholar
• Leonard GD, Low JA, Berman AW, Swain SM. CA 125 elevation in breast cancer: a case report and review of the literature. The Breast Journal 2004; 10: 146–149
   PubMedGoogle Scholar
• Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005; 104: 257–263
   PubMed Web of Science ®Google Scholar
• Maguire HC, Greene MI. The neu (c-erbB-2) oncogene. Seminars in Oncology 1989; 16: 148–155
   PubMed Web of Science ®Google Scholar
• Meyer T, Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. British Journal of Cancer 2000; 82: 1535–1538
   PubMed Web of Science ®Google Scholar
• Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Research 1996; 16: 2295–2300
   PubMedGoogle Scholar
• Molina R, Jo J, Zanon G, Filella X, Farrus B, Munoz M, et al. Utility of c-erbB-2 in tissue and serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15-3. British Journal of Cancer 1996; 74: 1126–1131
   PubMed Web of Science ®Google Scholar
• Nichols HB, Trentham-Dietz A, Love RR, Hampton JM, Thi Hoang Anh P, Allred DC, et al. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiology. Biomarkers & Prevention 2005; 14: 41–47
   Google Scholar
• Norum LF, Erikstein B, Nustad K. Elevated CA 125 in breast cancer – a sign of advanced disease. Tumor Biology 2001; 22: 223–228
   PubMed Web of Science ®Google Scholar
• Omar YT, Behbehani AE, al-Naqeeb N, Motawy MM, Foudeh MO, Awwad AH, et al. Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer. International Journal of Biological Markers 1989; 4: 81–86
   PubMedGoogle Scholar
• Pichon MF, Hacene K, Guepratte S, Neumann R. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. Clinical Laboratory 2004; 50: 163–170
   PubMedGoogle Scholar
• Pilo A, Zucchelli GC, Cohen R, Bizollon C, Capelli G, Cianetti A, et al. Comparison of immunoassay for tumor markers CA 19-9, CA 15-3 and CA 125: data from an international quality assessment scheme. Tumori 1995; 81: 117–124
   PubMedGoogle Scholar
• Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993; 8: 2917–2923
   PubMed Web of Science ®Google Scholar
• Safi F, Kohler I, Rottinger E, Beger HG. The value of tumor marker CA 15-3 in diagnosis and monitoring breast cancer. Cancer 1991; 68: 574–582
   PubMedGoogle Scholar
• Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncology Reports 2004; 11: 1331–1336
   PubMedGoogle Scholar
• Schwartz MK, Smith C, Schwartz DC, Dnistrian A, Neiman I. Monitoring therapy by serum HER-2/neu. International Journal of Biological Markers 2000; 15: 324–329
   PubMed Web of Science ®Google Scholar
• Shering S, Sherry F, McDermott E, O'Higgins N, Duffy MJ. Preoperative CA 15-3 concentrations predict outcome in breast cancer. Cancer 1998; 83: 2521–2527
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind CH. 1997. International Union Against Cancer (UICC). In: TNM Classification of Malignant Tumours, 5th edition. New York, NY: Wiley-Liss.
   Google Scholar
• Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE, et al. Pattern of p53 gene mutations in breast cancers in women of the Midwestern United States. Journal of National Cancer Investigations 1992; 84: 246–252
   PubMed Web of Science ®Google Scholar
• Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. International Journal of Cancer 2000; 89: 329–336
   PubMed Web of Science ®Google Scholar
• Tampellini M, Berruty A, Bitossi R, Gorzegno G, Alabiso I, Bottini A, et al. Prognostic significance of changes in CA 15-3 serum level during chemotherapy in metastatic breast cancer patients. Breast Cancer Research and Treatment 2006; 98: 241–248
   PubMed Web of Science ®Google Scholar
• Watanabe N, Miyamoto M, Tokuda Y, Kubota M, Ando Y, Tajima T, et al. Serum c-erbB-2 in breast cancer patients. Acta Oncologica 1994; 33: 901–904
   PubMed Web of Science ®Google Scholar
• Weiss SE, Tartter P, Ahmed S, Brower S, Brusco C, Bossolt K, et al. Ethnic differences in risk and prognostic factors for breast cancer. Cancer 1995; 76: 268–274
   PubMed Web of Science ®Google Scholar
• Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell/cell adhesion by the membrane-associated mucin episialin/MUC1. Molecular Biology of the Cell 1996; 7: 565–577
   PubMed Web of Science ®Google Scholar